1. Increasing prevalence of plantar fasciitis: The rising incidence of plantar fasciitis globally is a major growth driver for the plantar fasciitis treatment market. Factors such as sedentary lifestyle, obesity, and aging population contribute to the increasing prevalence of this condition, thereby driving the demand for effective treatment options.
2. Technological advancements in treatment options: The plantar fasciitis treatment market is experiencing significant growth due to the development of advanced treatment options such as shock wave therapy, ultrasound therapy, and minimally invasive surgical procedures. These technological advancements offer more effective and less invasive alternatives to traditional treatment methods, driving the market growth.
3. Growing awareness and healthcare infrastructure: Increasing awareness about the symptoms and treatment options for plantar fasciitis, along with the expansion of healthcare infrastructure in emerging economies, is contributing to the market growth. This has led to early diagnosis and treatment of plantar fasciitis, thus driving the demand for treatment options.
4. Cost-effective and non-invasive treatment options: The demand for cost-effective and non-invasive treatment options for plantar fasciitis is driving the market growth. Patients are increasingly opting for conservative treatment methods such as orthotic devices, physical therapy, and corticosteroid injections, which are less expensive and have minimal side effects compared to surgical interventions.
Industry
Report Coverage | Details |
---|---|
Segments Covered | Treatment Type, Indication, End-Use |
Regions Covered | • North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA) |
Company Profiled | 3M A. Algeo. Bauerfeind USA Hanger, OrthoBethesda OrthoMed, Ottobock Pfizer, Revance Therapeutics, Sanofi Shapecrunch |
1. Lack of awareness and underdiagnosis: One of the major restraints in the plantar fasciitis treatment market is the lack of awareness among patients and healthcare professionals about the condition. This often leads to underdiagnosis and delayed treatment, impacting the market growth.
2. High cost of advanced treatment options: Despite technological advancements, the high cost of advanced treatment options such as shock wave therapy and minimally invasive surgical procedures acts as a restraint to the market growth. These treatments may not be affordable for a significant portion of the population, limiting their accessibility.
3. Adverse effects associated with certain treatments: Some of the treatment options for plantar fasciitis, such as corticosteroid injections, may have associated adverse effects such as tissue atrophy and plantar fascia rupture. These risks can deter patients from opting for certain treatment options, impacting the market growth.